Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

@article{Grothey2013RegorafenibMF,
  title={Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.},
  author={Axel M Grothey and Eric Van Cutsem and Alberto F. Sobrero and Salvatore Siena and Alfredo Falcone and Marc Ychou and Yves Humblet and Olivier Bouch{\'e} and Laurent Mineur and Carlo Barone and Antoine A. Adenis and Josep Tabernero and Takayuki Yoshino and H. P. Lenz and Richard M. Goldberg and Daniel J. Sargent and Frank Cihon and Lisa Cupit and Andrea Veiga Wagner and Dirk Laurent},
  journal={Lancet},
  year={2013},
  volume={381 9863},
  pages={303-12}
}
BACKGROUND No treatment options are available for patients with metastatic colorectal cancer that progresses after all approved standard therapies, but many patients maintain a good performance status and could be candidates for further therapy. An international phase 3 trial was done to assess the multikinase inhibitor regorafenib in these patients… CONTINUE READING